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Development of PD-1 and PD-L1 inhibitors
as a form of cancer immunotherapy: a
comprehensive review of registration trials
and future considerations
Jun Gong1, Alexander Chehrazi-Raffle2, Srikanth Reddi2 and Ravi Salgia3*
Abstract
Early preclinical evidence provided the rationale for programmed cell death 1 (PD-1) and programmed death ligand
1 (PD-L1) blockade as a potential form of cancer immunotherapy given that activation of the PD-1/PD-L1 axis
putatively served as a mechanism for tumor evasion of host tumor antigen-specific T-cell immunity. Early-phase
studies investigating several humanized monoclonal IgG4 antibodies targeting PD-1 and PD-L1 in advanced solid
tumors paved way for the development of the first PD-1 inhibitors, nivolumab and pembrolizumab, approved by
the Food and Drug Administration (FDA) in 2014. The number of FDA-approved agents of this class is rapidly
enlarging with indications for treatment spanning across a spectrum of malignancies. The purpose of this review is
to highlight the clinical development of PD-1 and PD-L1 inhibitors in cancer therapy to date. In particular, we focus
on detailing the registration trials that have led to FDA-approved indications of anti-PD-1 and anti-PD-L1 therapies
in cancer. As the number of PD-1/PD-L1 inhibitors continues to grow, predictive biomarkers, mechanisms of
resistance, hyperprogressors, treatment duration and treatment beyond progression, immune-related toxicities, and
clinical trial design are key concepts in need of further consideration to optimize the anticancer potential of this
class of immunotherapy.
Keywords: PD-1 inhibitor, PD-L1 inhibitor, Clinical trials, Biomarkers, Immune checkpoint, Hyperprogressors,
Treatment beyond progression, Microbiome, Immune-related toxicity
Background
The programmed cell death protein 1 receptor (PD-1)
receptor was first described in the early 1990s given its
expression during induction of apoptosis in a T-cell
hybridoma [1, 2]. Since its initial discovery several
groups have identified that engagement of PD-1 through
its ligand, programmed death ligand 1 (PD-L1),
negatively regulates T-cell-mediated immune responses
[3–6]. Early preclinical evidence suggested that activa-
tion of PD-1/PD-L1 signaling could serve as a mechan-
ism for tumors to evade an antigen-specific T-cell
immunologic response [6–8]. Consequently, the
hypothesis was developed that PD-1/PD-L1 blockade
may be an effective cancer immunotherapy (Fig. 1).
Initial phase I studies investigating several human-
ized monoclonal IgG4 antibodies targeting PD-1 and
PD-L1 in advanced solid tumors were soon conducted
and paved way for the development of the first PD-1
inhibitors, nivolumab and pembrolizumab, approved
by the Food and Drug Administration (FDA) [9–11].
Immune checkpoint inhibitors targeting the PD-1/PD-
L1 axis are now approved in the treatment of several
malignancies ranging from classical Hodgkin lymph-
oma to head and neck squamous cell carcinoma
(HNSCC) [12].
Since the approval of pembrolizumab for the treat-
ment of advanced melanoma in September 2014, the
clinical development of PD-1 and PD-L1 inhibitors as
anticancer agents has broadened (Table 1). Presently, the
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FDA has approved PD-1/PD-L1 inhibitors for the treat-
ment of nine cancer types (Fig. 2). The purpose of this
review is to highlight the clinical development of PD-1
and PD-L1 inhibitors in cancer therapy to date. In
particular, we focus on detailing the registration trials
that have led to FDA-approved indications of anti-PD-1
and anti-PD-L1 therapies in cancer and discuss future
considerations important to optimizing their antitumor
efficacy.
A literature search was conducted in MEDLINE using
the following key words: “programmed death 1,” pro-
grammed death-ligand 1,” “PD-1,” “PD-L1,” “immune
checkpoint inhibitor” and limited to published studies of
English language up to October 1, 2017. Studies were
further restricted to registration trials leading to FDA-
approved indications in cancer therapy. An additional
manual search was performed to include preliminary
results from abstracts of potential relevance.
Melanoma
Pembrolizumab
On September 4, 2014, pembrolizumab (humanized
monoclonal IgG4 antibody) became the first PD-1 inhibi-
tor to receive approval for patients with advanced or
Fig. 1 Mechanism of action of PD-1 and PD-L1 inhibitors. The programmed cell death 1 (PD-1) receptor is expressed on activated T cells, B cells,
macrophages, regulatory T cells (Tregs), and natural killer (NK) cells. Binding of PD-1 to its B7 family of ligands, programmed death ligand 1 (PD-
L1 or B7-H1) or PD-L2 (B7-DC) results in suppression of proliferation and immune response of T cells. Activation of PD-1/PD-L1 signaling serves as
a principal mechanism by which tumors evade antigen-specific T-cell immunologic responses. Antibody blockade of PD-1 or PD-L1 reverses this
process and enhances antitumor immune activity. TCR, T-cell receptor; MHC, major histocompatibility complex; APC, antigen-presenting cell
Table 1 Overview of PD-1/PD-L1 inhibitors, mechanisms of action, trial designations and approved companion diagnostics
Agent Mechanism of action Trial name(s) FDA-approved PD-L1 companion diagnostic
Pembrolizumab PD-1 inhibitor KEYNOTE Primary antibody: 22C3 (Dako)
IHC scoring: Tumor cell membrane
Therapeutic developer: Merck
Nivolumab PD-1 inhibitor CheckMate Primary antibody: 28-8 (Dako)
IHC scoring: Tumor cell membrane
Therapeutic developer: BMS
Atezolizumab PD-L1 inhibitor IMVigor (UC), POPLAR (NSCLC), OAK (NSCLC) Primary antibody: SP142 (Ventana)
IHC scoring: Tumor cell membrane,
infiltrating immune cells
Therapeutic developer: Genentech
Durvalumab PD-L1 inhibitor Study 1108 Primary antibody: SP263 (Ventana)
IHC scoring: Tumor cell membrane
Therapeutic developer: AstraZeneca
Avelumab PD-L1 inhibitor JAVELIN Primary antibody: 73-10 (Dako)a
IHC scoring: Tumor cell membrane
Therapeutic developer: Merck, Pfizer
PD-1 programmed cell death 1, PD-L1 programmed death ligand 1, FDA Food and Drug Administration, IHC immunohistochemistry, BMS Bristol-Myers Squibb,
UC urothelial carcinoma, NSCLC non-small cell lung cancer
a For research use only
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unresectable melanoma based on the findings from the
KEYNOTE-001 study [13, 14]. In this phase I multicenter,
international, open-label, randomized expansion of the
KEYNOTE-001 cohort, 173 patients with advanced or
unresectable melanoma who had previously failed treat-
ment with ipilimumab and a BRAF inhibitor (if
BRAFV600-mutated) were treated with pembrolizumab
[14]. Patients were randomly assigned to treatment with
pembrolizumab intravenous (IV) at 2 mg/kg every 3 weeks
or 10 mg/kg every 3 weeks. The primary study endpoint
was overall response rate (ORR) per RECIST 1.1. The
ORR was 26% in both the pembrolizumab 2 mg/kg and
10 mg/kg groups (Table 2). Grade 3-4 drug-related
adverse events (AEs) occurred in 15% of the pembrolizu-
mab 2 mg/kg group (most common fatigue 6%) and 8% of
the pembrolizumab 10 mg/kg group (1 each of diarrhea,
rash, dyspnea, hypoxia, maculopapular rash, pancreatitis,
and musculoskeletal pain) [14]. In an update of
KEYNOTE-001, findings after a median follow-up dur-
ation of 18 months for all patients were published [15].
Progression-free survival (PFS) at 6 months was 45%,
median overall survival (OS) was 25.9 months, and ORR
34% in ipilimumab-treated and 45% in ipilimumab-naïve
patients. Pembrolizumab was well tolerated as 14% of all
patients experienced grade ≥ 3 AEs.
On December 18, 2015, pembrolizumab received an
expanded first-line indication to include previously-
untreated advanced melanoma regardless of BRAF muta-
tion status following the results of the KEYNOTE-006
trial [16]. In this international, randomized, open-label
phase 3 study, pembrolizumab 10 mg/kg every 2 weeks
or every 3 weeks vs. ipilimumab 3 mg/kg every 3 weeks
was evaluated in patients with advanced, unresectable
stage III or IV melanoma who had received ≤1 previous
systemic therapy for advanced disease. Primary end-
points were PFS and OS and 6-month PFS for patients
who received pembrolizumab every 2 weeks and every
3 weeks was 47.3% and 46.4%, respectively, compared to
26.5% for those who received ipilimumab (hazard ratio
(HR) for disease progression 0.58 for both pembrolizu-
mab regimens vs. ipilimumab, 95% confidence interval
(CI) 0.46-0.72 and 0.47-0.72, respectively, p < 0.001).
One-year OS and ORR rates were significantly improved
in patients receiving either doses of pembrolizumab
Fig. 2 Timeline of FDA approvals for PD-1 and PD-L1 inhibitors in cancer therapy. The Food and Drug Administration approvals of programmed
cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors detailed by agent, date of approval, and tumor type. NSCLC, non-small cell
lung cancer; HNSCC, head and neck squamous cell carcinoma; MSI-H, microsatellite instability-high; RCC, renal cell carcinoma; HCC, hepatocellular
carcinoma; UC, urothelial carcinoma; MCC, Merkel cell carcinoma
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compared to ipilimumab as well (Table 2). The most
common grade 3-5 AEs of special interest were colitis
(1.4%, pembrolizumab every 2 weeks), colitis (2.5%) and
hepatitis (1.8%, pembrolizumab every 3 weeks), and col-
itis (7.0%, ipilimumab) [16].
Furthermore, the FDA approved a labeling update for
pembrolizumab in ipilimumab-refractory melanoma based
on findings from KEYNOTE-002 [17]. This study com-
pared pembrolizumab and investigator-choice chemother-
apy (ICC) for the treatment of unresectable stage III or
stage IV ipilimumab and/or BRAF inhibitor-refractory
melanoma. Patients (n = 540) were randomized to receive
pembrolizumab 2 mg/kg every 3 weeks, pembrolizumab
10 mg/kg every 3 weeks, or ICC (paclitaxel plus
carboplatin, paclitaxel, carboplatin, dacarbazine, or temo-
zolomide). There was no statistically significant difference
in OS between both pembrolizumab arms and
chemotherapy at interim analysis. Doses of pembrolizu-
mab 2 mg/kg (HR 0.57, 95% CI 0.45-0.73, p < 0.001) and
10 mg/kg (HR 0.50, 95% CI 0.39-0.64, p < 0.001) showed
superior median PFS when compared to chemotherapy.
Response rates were 21% in the pembrolizumab 2 mg/kg
group and 25% in the 10 mg/kg group compared to 4% in
the chemotherapy arm (p < 0.0001). Incidence of grade 3-
4 treatment-related AEs was higher in those given
chemotherapy (26%) than in those given pembrolizumab
2 mg/kg group (11%) and pembrolizumab 2 mg/kg group
(14%) [17].
Table 2 Registration trials leading to the FDA approval of PD-1/PD-L1 inhibitors in melanoma
Study/Agent Tumor (n) Line of therapy Experimental arm Control arm Primary endpointa Ref
KEYNOTE-001
(phase I)/
pembrolizumab
Advanced
melanoma
(n = 173)
Previously treated
with ipilimumab
and/or BRAF inhibitor
Pembrolizumab 2 mg/kg
or 10 mg/kg every
3 weeks
ORR 26% (both doses;
difference 0%, 95%
CI 14-13, p = 0.96)
14
KEYNOTE-006
(phase III)/
pembrolizumab
Advanced
melanoma
(n = 834)
First-line (regardless
of BRAF mutations
status)
Pembrolizumab 10 mg/kg
every 2 weeks OR every
3 weeks
Ipilimumab 3 mg/kg
every 3 weeks X4
cycles
PFS (6-month) 47.3% vs. 46.4%
vs. 26.5% (HR 0.58 for both
pembrolizumab regimens vs.
ipilimumab 95% CI 0.46-0.72
and 0.47-0.72, respectively,
p < 0.001)
OS (1-year) 74.1% vs. 68.4%
vs. 58.2% (HR pembrolizumab
every 2 weeks 0.63, 95% CI
0.47-0.83, p = 0.0005; HR
pembrolizumab every 3 weeks
0.69, 95% CI 0.52-0.90,
p = 0.0036)
16
KEYNOTE-002
(phase II)/
pembrolizumab
Advanced
melanoma
(n = 540)
Refractory to
ipilimumab and/or
BRAF inhibitor
Pembrolizumab 2 mg/kg
every 3 weeks OR 10
mg/kg every 3 weeks
ICC (paclitaxel+
carboplatin, paclitaxel,
carboplatin, dacarbazine,
or temozolomide)
PFS 2 mg/kg (HR 0.57 95% CI
0.45-0.73, p < 0.001) and
10 mg/kg (HR 0.50, 95% CI
0.39-0.64, p < 0.001) compared
to ipilimumab
No superiority in OS at
this interim analysis
17
CheckMate 037
(phase III)/
nivolumab
Stage IIIC or
IV melanoma
(n = 405)
Second-line Nivolumab 3 mg/kg
every 2 weeks
Dacarbazine 1000 mg/
m2 every 3 weeks
OR carboplatin
AUC 6 + paclitaxel
175 mg/m2 every
3 weeks
ORR 31.7% (95% CI 23.5-40.8)
vs. 10.6% (95% 3.5-23.1)
18
CheckMate 069
phase III)/
nivolumab/ipilimumab
BRAFV600-WT
unresectable or
metastatic
melanoma
(n = 142)
First-line Nivolumab 1 mg/kg +
ipilimumab 3 mg/kg every
3 weeks X4 cycles then
nivolumab alone every
2 weeks
Ipilimumab 3 mg/kg every
3 weeks
ORR 61% vs. 11% (p < 0.001) 19
CheckMate 067
phase III)/
nivolumab/ipilimumab
Unresectable or
metastatic
melanoma
(n = 945)
First-line Arm 1: Nivolumab
3 mg/kg every 2 weeks
Arm 2: nivolumab
1 mg/kg and ipilimumab
3 mg/kg every 3 weeks
for 4 doses followed
by nivolumab 3 mg/kg
of every 2 weeks
Ipilimumab 3 mg/kg every
3 weeks
PFS 6.9 mos (HR compared to
ipilimumab 0.57, 99.5% CI
0.43-0.76, p < 0.001 vs. 11.5 mo
(HR 0.42, 99.5% CI 0.31-0.57,
p < 0.001 compared to
ipilimumab) vs. 2.9 mos
20
a Order of results refers to the experimental arm and control arm, respectively. In trials with more than one experimental arm, the endpoints are in the
same order as documented in the experimental arm column
FDA Food and Drug Administration, PD-1 programmed cell death 1, PD-L1 programmed death ligand 1, ORR overall response rate, CI confidence
interval, PFS progression-free survival, HR hazard ratio, OS overall survival, ICC investigator-choice chemotherapy, AUC area under curve, WT wild-type
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Nivolumab
On December 22, 2014, nivolumab was first approved as
second-line treatment of unresectable or metastatic mel-
anoma based on the CheckMate 037 trial [18]. This ran-
domized controlled, open-label, international phase III
study randomized 272 patients with unresectable stage
IIIC or IV melanoma progressing after anti-CTLA-4
treatment or after anti-CTLA-4 treatment and a BRAF
inhibitor for BRAFV600-mutated tumors to IV nivolumab
3 mg/kg every 2 weeks and 133 to ICC (Table 2). Posi-
tive PD-L1 expression was defined as ≥5% of tumor cells
exhibiting PD-L1 staining (IHC 28-8 antibody) of any in-
tensity in a section containing ≥100 evaluable cells. The
ORR was 31.7% in the nivolumab group and 10.6% in
the chemotherapy group (Table 2). In patients with PD-
L1 positivity, ORR was 43.6% compared to 9.1% of the
chemotherapy group. Grade ≥ 3 nivolumab-related AEs
were seen in 9% of patients and included elevated lipase,
elevated alanine aminotransferase (ALT), fatigue, and
anemia. Grade ≥ 3 AEs occurred in 32% of chemotherapy
patients, the most common of which were neutropenia,
anemia, and thrombocytopenia.
The combination of nivolumab and ipilimumab was
later approved as first-line treatment for BRAFV600-wild-
type unresectable or metastatic melanoma on October 1,
2015 based on results from CheckMate 069 [19]. This
randomized, double-blinded phase III trial, compared
nivolumab 1 mg/kg in combination with ipilimumab
3 mg/kg (every 3 weeks X4 cycles then nivolumab alone
every 2 weeks) against ipilimumab 3 mg/kg monother-
apy (every 3 weeks) as first-line treatment in 142 pa-
tients with advanced melanoma. Objective response
occurred in 61% of patients with BRAFV600-wild-type tu-
mors in the combination group compared with 11% of
patients in the monotherapy group. Of note, overall re-
sponse was independent of PD-L1 status in both the
combination group (58% for PD-L1-positive (≥5%) tu-
mors vs. 55% for PD-L1-negative tumors) and the mono-
therapy group (18% for PD-L1- positive tumors and 4%
for PD-L1 negative tumors). In patients with BRAFV600-
mutated tumors, the ORR was 52% in the combination
group compared with 10% in the monotherapy group.
Grade ≥ 3 AEs occurred more frequently in the combin-
ation group (54%) than in the monotherapy group
(24%), the most common of which were colitis, diarrhea,
and elevated ALT. Ipilimumab monotherapy-related
grade ≥ 3 AEs were seen in 24% of patients, the most
common of which were diarrhea and colitis.
On January 23, 2016, nivolumab and ipilimumab com-
bination therapy received an expanded approval for
unresectable or metastatic melanoma irrespective of
BRAFV600 mutation status based on results of the
CheckMate 067 trial [20]. In this phase III trial, patients
with untreated, unresectable or metastatic melanoma
were randomized to receive nivolumab 3 mg/kg every 2
weeks, nivolumab 1 mg/kg and ipilimumab 3 mg/kg
every 3 weeks for 4 doses followed by nivolumab 3 mg/
kg every 2 weeks, or ipilimumab 3 mg/kg. Median PFS
was 6.9 months in the nivolumab group, 11.5 months in
the combination group, and 2.9 months in the ipilimu-
mab group (Table 2). Longer OS was shown with nivolu-
mab and combination therapy compared with
ipilimumab alone across all subgroups (PD-L1 status,
BRAFV600 status, and metastasis stage). The incidence of
grade ≥ 3 AEs was greater in the combination group
(55%) than in nivolumab or ipilimumab alone (16.3%
and 27.3%, respectively). The most common grade ≥ 3
AEs in the combination group were diarrhea, colitis, and
increased ALT and aspartate aminotransferase (AST)
whereas the most frequent grade ≥ 3 AEs in the mono-
therapy arms were fatigue and diarrhea.
Non-small cell lung cancer
Pembrolizumab
On October 2, 2015, pembrolizumab was approved for
treatment of previously-treated advanced or metastatic
PD-L1-positive non-small cell lung cancer (NSCLC)
[21]. As part of the KEYNOTE-001 phase I study, 550
patients were treated with either pembrolizumab at a
dose of 2 mg/kg every 2 weeks or 10 mg/kg every 2 or
3 weeks (Table 3). The primary endpoints were antitu-
mor activity per RECIST 1.1 and safety. Of the 61 pa-
tients with tumors identified as strongly positive for PD-
L1 (PD-L1 ≥ 50% based on the companion diagnostic
PD-L1 immunohistochemistry (IHC) 22C3 assay), the
ORR for those receiving pembrolizumab 2 mg/kg was
28% (95% CI 12.1-49.4%) as compared to 40% (95% CI
22.4-61.2) and 41% (95% CI 24.7-59.3%) in patients re-
ceiving pembrolizumab 10 mg/kg every 2 weeks and
every 3 weeks, respectively. The most commonly occur-
ring (> 20%) AEs included fatigue, decreased appetite,
dyspnea, and cough. Immune-mediated AEs occurred in
13% of patients and included pneumonitis, colitis, hypo-
physitis, and thyroid disorders [21].
Updated long-term OS data for patients with
previously-treated or treatment-naïve advanced or
metastatic NSCLC were subsequently presented for the
phase Ib KEYNOTE-001 study [22]. As compared to
earlier studies that stratified tumor proportion score
(TPS) cutoff of 1-50% and ≥50% PD-L1 staining of
tumor cells, these investigators assessed a PD-L1 stain-
ing cutoff of ≥1% on tumor cells. Patients received
either pembrolizumab 2 mg/kg every 3 weeks or
10 mg/kg every 2 or 3 weeks. Using a PD-L1 TPS cutoff
of ≥1%, median OS was 22.1 months (95% CI 17.1-27.2)
for treatment-naive patients and 10.6 months (95% CI
8.6-13.3) for previously-treated patients, supporting the
efficacy of pembrolizuamb in patients with a PD-L1
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TPS ≥1% [22]. KEYNOTE-001 investigators attempted
to define a tumor PD-L1 expression level associated
with an enhanced likelihood of benefit as well as valid-
ate the safety and antitumor activity of pembrolizumab
in patients with advanced NSCLC and PD-L1 ≥ 50%
expression [23]. Patients received pembrolizumab
2 mg/kg every 3 weeks or 10 mg/kg every 2 or 3 weeks
and were randomized to either a training group or
validation group. In the training group, the PD-L1 cut-
off was selected by immune-related response criteria by
investigator review; in the validation group,
membranous PD-L1 expression ≥50% was selected as
the cutoff. The ORR was 45.2% in the patients with
PD-L1 ≥ 50%, including 43.9% in previously-treated
patients and 50.0% in untreated patients. These values
exceeded the response rate in the training group of
36.6%. Toxicities of grade ≥ 3 were reported in 47/495
patients (9.5%) and were most commonly dyspnea
(3.8%), pneumonitis (1.8%), decreased appetite (1%),
and asthenia (1%) [23].
Following KEYNOTE-001, KEYNOTE-010 was a phase
II/III clinical trial that randomized 1034 patients to pem-
brolizumab (2 or 10 mg/kg every 3 weeks) vs. docetaxel
(75 mg/m2) for PD-L1-positive NSCLC that progressed
after platinum-based chemotherapy or a tyrosine kinase
inhibitor (TKI) for those with an EGFR-sensitizing muta-
tion or ALK gene rearrangement [24]. For patients with
PD-L1 expression ≥1%, median OS for pembrolizumab
2 mg/kg (HR 0.71, 95% CI 0.58-0.88, p = 0.0008) and
10 mg/kg (HR 0.61, 95% CI 0.49-0.75, p < 0.0001) and
median PFS for pembrolizumab 10 mg/kg (HR 0.79, 95%
CI 0.66-0.94, p = 0.004) were significantly improved
Table 3 Registration trials leading to the FDA approval of PD-1/PD-L1 inhibitors in lung cancer
Study/Agent Tumor (n) Line of therapy Experimental arm Control arm Primary endpoint Ref
KEYNOTE-001
(phase Ib)/
pembrolizumab
Advanced
NSCLC
(n = 550)
PD-L1 positive
(≥1%)
progressing after
platinum-based
therapy
Pembrolizumab 2 mg/kg every
3 weeks OR 10 mg/kg every
2 or 3 weeks
ORR 28% (95% CI
12.1-49.4%) vs. 40%
(95% CI 22.4-61.2)
vs. 41% (95% CI
24.7-59.3%) for
PD-L1≥ 50%
OS 22.1 mo
(treatment-naïve,
95% CI 17.1-27.2)
vs. 10.6 mo
(previously-treated,
95% CI 8.6-13.3)
for PD-L1≥ 50%
21,
22
KEYNOTE-024
(phase III)/
pembrolizumab
Metastatic
NSCLC with
≥50% PD-L1
expression
(n = 305)
First-line Pembrolizumab 200 mg every
3 weeks
ICC (cisplatin/
carboplatin + pemetrexed,
cisplatin/carboplatin +
gemcitabine, or
carboplatin + paclitaxel)
PFS 10.3 mos vs. 6.0
mos (HR 0.50, 95%
CI 0.37-0.68,
p < 0.001)
25
KEYNOTE-021
(phase II)/
pembrolizumab
Advanced
NSCLC
(n = 123)
First line (in
combination with
platinum-doublet
chemotherapy)
Pembrolizumab 200 mg +
carboplatin AUC 5 mg/ml/min +
pemetrexed 500 mg/m2 every
3 weeks X4 cycles followed by
pembrolizumab (24 months
duration) and indefinite
maintenance pemetrexed
Carboplatin + pemetrexed
X4 cycles followed by
indefinite maintenance
pemetrexed
ORR 55% vs. 29%
(estimated
treatment difference
of 26%, 95% CI
9-42%, p = 0.0016)
26
CheckMate 017
(phase III)/
nivolumab
Metastatic
squamous
NSCLC
(n = 272)
Previously treated
with platinum-based
chemo
Nivolumab 3 mg/kg every
2 weeks
Docetaxel 75 mg/m2
every 2 weeks
OS 9.2 mo vs. 6.0
mos (HR 0.59, 95%
CI 0.44-0.79,
p < 0.001)
27
CheckMate 057
(phase III)/
nivolumab
Metastatic
non-squamous
NSCLC (n = 582)
Previously treated
with platinum-based
chemo
Nivolumab 3 mg/kg every
2 weeks
Docetaxel 75 mg/m2
every 3 weeks
OS 12.2 mos vs. 9.4
mos (HR 0.73, 96%
CI 0.59-0.89,
p = 0.002)
28
POPLAR (phase II)/
OAK (phase III)/
atezolizumab
NSCLC (POPLAR
n = 287, OAK
n = 1225)
Second-line Atezolizumab 1200 mg every
3 weeks
Docetaxel 75 mg/m2 POPLAR: OS 12.6 mos
vs. 9.7 mos (HR 0.7,
95% CI 0.53-0.99,
p= 0.04)
OAK: OS 13.8 mos
vs. 9.6 mos (HR 0.73,
95% CI 0.62-0.87,
p = 0.0003)
29,
30
FDA Food and Drug Administration, PD-1 programmed cell death 1, PD-L1 programmed death ligand 1, NSCLC non-small cell lung cancer, ORR overall response
rate, CI confidence interval, OS overall survival, ICC investigator-choice chemotherapy, PFS progression-free survival, HR hazard ratio, AUC area under curve
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compared to docetaxel with a trend towards improved
PFS with pembrolizumab 2 mg/kg. Pembrolizumab at
both doses was superior to docetaxel in OS and PFS in
those with ≥50% PD-L1 expression. Grade ≥ 3 treatment-
related AEs occurred in 13% of the pembrolizumab 2 mg/
kg group, 16% of the pembrolizumab 10 mg/kg group,
and 35% of the docetaxel group. Deaths attributed to
treatment occurred in 3 patients in the pembrolizumab
2 mg/kg group (2 of pneumonitis and 1 pneumonia), 3 pa-
tients in the pembrolizumab 10 mg/kg group (myocardial
infarction, pneumonia, and pneumonitis), and 5 patients
in the docetaxel group [24].
On October 24, 2016, pembrolizumab received
approval as first-line treatment for metastatic NSCLC
with ≥50% PD-L1 expression and without EGFR or ALK
genomic tumor aberrations [25]. In the phase III
KEYNOTE-024 trial, 305 patients were randomized to
receive either pembrolizumab 200 mg every 3 weeks or
ICC (platinum-based) for 4-6 cycles. Median PFS was
10.3 months in the pembrolizumab group as compared
to 6.0 months in the chemotherapy group (HR 0.50, 95%
CI 0.37-0.68, p < 0.001). Grade ≥ 3 treatment-related AEs
occurred in 26.6% of the pembrolizumab group and
53.3% of the chemotherapy group [25].
On May 10, 2017, pembrolizumab received approval
to be given in combination with pemetrexed and carbo-
platin as first-line treatment of metastatic NSCLC, irre-
spective of PD-L1 expression [26]. In the phase II
KEYNOTE-021 open-label trial, 123 patients with stage
IIIB or IV NSCLC who did not demonstrate targetable
EGFR mutations or ALK translocations received either
pembrolizumab 200 mg plus pemetrexed 500 mg/m2
and carboplatin area under the curve (AUC) 5 mg/mL/
min every 3 weeks for 4 cycles follow by pembrolizumab
200 mg for 24 months and indefinite pemetrexed main-
tenance therapy, or pemetrexed 500 mg/m2 and carbo-
platin AUC 5 mg/mL/min followed by indefinite
pemetrexed maintenance therapy alone. The primary
endpoint ORR was 55% (33/60 patients) in the pembroli-
zumab plus chemotherapy group compared to 29% (18/
63 patients) in the chemotherapy alone group, equating
to an estimated treatment difference of 26% (95% CI 9-
42%, p = 0.0016). The most common all-grade
treatment-related AEs in the pembrolizumab arm vs.
chemotherapy alone arm were fatigue (64% vs. 40%),
nausea (58% vs. 44%), and anemia (32% vs. 53%).
Nivolumab
Nivolumab was approved as treatment for metastatic
squamous NSCLC on March 4, 2015 based on the
CheckMate 017 trial [27]. In this phase III study,
patients who progressed during or after 1 prior
platinum-containing chemotherapy regimen were ran-
domized to receive nivolumab 3 mg/kg every 2 weeks or
docetaxel 75 mg/m2 every 3 weeks (Table 3). The
primary endpoint was OS and a key secondary endpoint
included efficacy based on tumor cell PD-L1 expression
levels of 1%, 5% or 10%. Median OS was 9.2 months in
the nivolumab group versus 6.0 months in the docetaxel
group, and OS at 1 year was 42% in the nivolumab
group versus 24% in the docetaxel group. PD-L1 expres-
sion was not predictive across any of the efficacy end-
points. Fewer all-grade treatment-related AEs occurred
with nivolumab (58%) than with docetaxel (86%). The
most frequently reported AEs were fatigue, decreased
appetite, and asthenia with nivolumab compared to neu-
tropenia, fatigue, and alopecia in the docetaxel arm.
Grade ≥ 3 AEs were found in 7% of patients with nivolu-
mab (including colitis and pneumonitis) compared 57%
with docetaxel (including hemotologic toxicity and
infections).
The CheckMate 057 trial ushered in the FDA-
expanded approval of nivolumab in metastatic non-
squamous NSCLC on October 9, 2015 [28]. This phase
III trial enrolled 582 patients who had progressed during
or after platinum-based doublet chemotherapy to receive
nivolumab 3 mg/kg every 2 weeks or docetaxel 75 mg/
m2 every 3 weeks. The primary endpoint was OS, which
was 12.2 months with nivolumab and 9.4 months with
docetaxel (Table 3). Treatment-related AEs occurred
more frequently with docetaxel (20%) than nivolumab
(7%). Grade ≥ 3 nivolumab-related AEs include fatigue,
nausea, asthenia, and diarrhea; grade ≥ 3 docetaxel-
related AEs included fatigue, anemia, and asthenia.
Atezolizumab
On October 18, 2016, atezolizumab (PD-L1 inhibitor)
was approved for previously-treated metastatic NSCLC
following the results of the POPLAR and OAK trials [29,
30]. POPLAR is an ongoing phase II trial that random-
ized 287 patients to receive atezolizumab 1200 mg or
docetaxel 75 mg/m2 with emphasis placed on PD-L1
expression of tumor cells and tumor-infiltrating immune
cells [29]. The primary endpoint was OS and at a mini-
mum follow-up of 13 months, atezolizumab had signifi-
cantly improved OS compared with docetaxel
(12.6 months vs. 9.7 months, p = 0.04). Increasing OS
improvement was seen in subgroups with greater tumor
cell and immune cell PD-L1 expression. However, unlike
OS, improved PFS and ORR was limited to only those
patients with the highest levels of PD-L1 expression
(tumor cell ≥50% or immune cell ≥10%). The most com-
mon atezolizumab-related AEs were pneumonia and
elevated AST levels.
Similarly, OAK is an ongoing phase III trial that ran-
domized patients with previously-treated advanced
NSCLC to atezolizumab 1200 mg every 3 weeks or
docetaxel 75 mg/m2 every 3 weeks [30]. Patients were
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stratified by PD-L1 expression, number of previous
chemotherapy regimens, and histology (squamous vs.
non-squamous). OS was improved regardless of PD-L1
expression (Table 3) though patients with the highest
PD-L1 expression experienced the greatest benefit from
atezolizumab with a median OS of 20.5 months com-
pared with 8.9 months in the docetaxel group. Grade ≥ 3
AEs were observed in 64% of patients in the atezolizu-
mab cohort and included fatigue and anemia. Docetaxel-
related grade ≥ 3 AEs were seen in 86% and were most
frequently febrile neutropenia, neutropenia, anemia, and
fatigue.
Durvalumab
Although not FDA approved, it is worthwhile to men-
tion that the PD-L1 inhibitor durvalumab was recently
granted FDA breakthrough designation in the adjuvant
treatment of locally advanced, unresectable NSCLC
based on the phase III PACIFIC trial [31]. The primary
endpoint was PFS, and 713 patients who did not demon-
strate PD after ≥2 cycles of platinum-based chemother-
apy concurrent with definitive RT were randomized to
durvalumab (10 mg/kg) or placebo within 1-42 days
after chemoradiotherapy every 2 weeks for up to 1 year.
Durvalumab demonstrated superior PFS (median PFS
16.8 months, 95% CI 13.0-18.1) over placebo
(5.6 months, 95% CI 4.6-7.8) in this setting (HR 0.52,
95% CI 0.42-0.65, p < 0.001). Safety was similar between
both treatment arms with 29.9% of durvalumab patients
and 26.1% of placebo patients experiencing grade 3-4
AEs. Improved outcomes were observed in the experi-
mental arm irrespective of PD-L1 status or histology.
Urothelial cancer
Pembrolizumab
On May 18, 2017, pembrolizumab received 2 FDA ap-
provals: in patients with locally advanced or metastatic
urothelial carcinoma (UC) who have disease progression
after platinum-containing chemotherapy and in patients
who are cisplatin-ineligible [32, 33]. In the phase III,
international KEYNOTE-045 trial, 542 patients with ad-
vanced UC showing ≥10% PD-L1 expression who had
previously failed platinum-based chemotherapy were
randomized to receive pembrolizumab 200 mg every
3 weeks or either paclitaxel, docetaxel, or vinflunine
[33]. Median OS was significantly higher in the pembro-
lizumab group compared to chemotherapy though there
was no significant difference in PFS (Table 4). Fewer
grade ≥ 3 AEs occurred with pembrolizumab compared
to the chemotherapy arm (15.0% vs. 49.4). Median OS
was also significantly improved with pembrolizumab
compared to chemotherapy (HR 0.57, 95% CI 0.37-0.88,
p = 0.005) in those with PD-L1 expression ≥10% but
there was no difference in PFS between arms in this
population. In the phase II, open-label KEYNOTE-052
trial, patients with locally advanced or metastatic urothe-
lial carcinoma who were cisplatin-ineligible received
first-line pembrolizumab 200 mg every 3 weeks until
progressive disease, unacceptable toxicity, or 24 months
of treatment. The primary endpoint was ORR per
RECIST 1.1. Of 370 enrolled patients, the ORR was 27%
(95% CI 22-32) in those who had enrolled for ≥4 months.
Grade ≥ 3 AEs occurred in 52 patients (14%) with 19
(5%) discontinuing therapy due to AEs [32].
Nivolumab
The FDA approved nivolumab on February 2, 2017
for locally advanced or metastatic UC following the
results from CheckMate 275 [34]. This phase II study
enrolled 270 patients who had experienced progres-
sion or recurrence after ≥1 platinum-based chemo-
therapy regimen to receive nivolumab 3 mg/kg every
2 weeks (Table 4). The primary endpoint was ORR in
all treated patients stratified by PD-L1 expression
(28.4% for ≥5%, 23.8% for ≥1%, and 16.1% for < 1%).
At median follow up of 7 months, OS was
11.30 months in the PD-L1 ≥ 1% subgroup and
5.95 months in the PD-L1 < 1% subgroup. Grade 3-4
AEs related to nivolumab included diarrhea and
fatigue.
Atezolizumab
On May 18, 2016, atezolizumab became the first PD-L1
inhibitor approved for locally advanced and metastatic
UC based on results of IMVigor 210 [35]. This phase II
trial enrolled 310 patients whose disease had progressed
after receiving platinum-based chemotherapy to receive
a fixed dose of atezolizumab 1200 mg every 3 weeks
(Table 4). PD-L1 status was subdivided by the percent-
age of PD-L1-positive immune cells in the tumor micro-
environment (TME): < 1%, ≥1% but < 5%, and ≥5%. The
primary endpoint was ORR. In all patients, ORR was
15%, a significant improvement compared to the histor-
ical response rate of 10%. In addition, subgroup analysis
showed a PD-L1-related response: PD-L1 ≥ 5% showed a
27% ORR, PD-L1 ≥ 1% showed 18% ORR, and PD < 1%
showed 8% response. Sixteen percent of patients experi-
enced grade 3-4 treatment-related AEs, the most com-
mon of which were fatigue, anemia, and hypertension.
Notably a recent press release for the confirmatory
IMVigor 211 trial reported a failure to meet the study’s
primary endpoint (see Discussion).
Accelerated approval of atezolizumab in the first-line
treatment of cisplatin-ineligible patients with locally ad-
vanced and metastatic UC occurred based on a separate
cohort of the IMVigor 210 trial [36]. This phase II,
single-arm trial administered atezolizumab 1200 mg
every 3 weeks to 119 treatment-naïve metastatic UC
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with stratification based on PD-L1 expression as in the
earlier IMVigor 210 trial. The primary endpoint was in-
dependently confirmed ORR per RECIST v1.1. In the
primary analysis, efficacy did not reach (PD-L1 ≥ 5% sub-
group) the pre-specified ORR of 10% after a median
follow-up of 8.5 months. After a 17.2 month median fol-
low up duration, the ORR increased to 28% in the PD-
L1 ≥ 5% subgroup, 21% in the ≥1% PD-L1 but < 5%
group, and 21% in the PD-L1 < 1% group. Interestingly,
median OS was 15.9 months in all patients, 12.3 months
in PD-L1 ≥ 5% patients, and 19.1 months in PD-L1 < 5%
patients. The most common grade 3-4 treatment-related
AEs were fatigue and elevated AST and ALT.
Durvalumab
Durvalumab received FDA approval on May 1, 2017 for
the treatment of platinum-refractory locally advanced or
metastatic UC based on results from Study 1108 [37]. In
this phase I/II dose-escalation and expansion study, 61
patients who had progressed on, been ineligible for, or
refused prior therapies for advanced disease were en-
rolled to receive the PD-L1 inhibitor durvalumab
10 mg/kg of every 2 weeks. Patients were initially en-
rolled regardless of PD-L1 expression, but enrollment
was later restricted to patients with ≥5% PD-L1 expres-
sion on tumor cells after preliminary data suggested PD-
L1 was expressed more commonly on immune cells than
tumor cells. The primary endpoint was safety and of 42
treated patients, grade ≥ 3 AEs occurred in 3 patients. Of
note, the ORR was 31.0% in all 42 patients, 46.4% in the
PD-L1-positive subgroup, and 0% in the PD-L1-negative
subgroup.
In an update of Study 1108, results were presented re-
garding the efficacy and tolerability of durvalumab
10 mg/kg every 2 weeks up to 12 months [38]. High PD-
L1 expression was defined as ≥25% of tumor or immune
cells (Ventana SP263 assay). The primary endpoint was
ORR using RECIST 1.1 (Table 4). Of the 191 treated
Table 4 Registration trials leading to the FDA approval of PD-1/PD-L1 inhibitors in urothelial carcinoma and renal cell carcinoma
Study/Agent Tumor (n) Line of therapy Experimental
arm
Control arm Primary endpoint Ref.
KEYNOTE-052
(phase II)/
pembrolizumab
Urothelial carcinoma
(n = 370)
First-line cisplatin-
ineligible
Pembrolizumab
200 mg every
3 weeks
ORR 24% (95% CI 20-29) 32
KEYNOTE-045
(phase III)/
pembrolizumab
Urothelial carcinoma
(n = 542)
Refractory to platinum-
based chemotherapy
Pembrolizumab
200 mg every
3 weeks
Paclitaxel 175 mg/m2
OR docetaxel
75 mg/m2 OR vinflunine
320 mg/m2
OS 10.3 mos vs. 7.4 mos
(HR 0.73, 95% CI 0.59-0.91,
p = 0.002)
PFS HR 0.98, 95% CI 0.81-1.19,
p = 0.42
33
CheckMate 275
(phase II)/
nivolumab
Advanced urothelial
carcinoma (n = 270)
Previously treated
with platinum-based
chemotherapy
Nivolumab
3 mg/kg every
2 weeks
ORR 28.4% (95% CI 18.9-39.5)
for 81 patients with PD-L1≥ 5%,
23.8% (95% CI 16.5-32.3) for
122 PD-L1≥ 1%, and 16.1%
(95% CI 10.5-23.1) for 143 with
PD-L1 < 1%
34
IMVigor 210 (phase
II)/atezolizumab
Urothelial carcinoma
(n = 315)
Previously treated with
platinum-based
chemotherapy
Atezolizumab
1200 mg every
3 weeks
ORR 27% (95% CI 19-37,
p < 0.0001) for PD-L1≥ 5%,
18% (95% CI 13-24, p = 0.0004)
for PD-L1≥ 1%, 15% (95% CI
11-20, p = 0.0058) for all patients
compared to historical control
35
IMVigor 210 (phase
II)/atezolizumab
Urothelial carcinoma
(n = 119)
First-line cisplatin-
ineligible
Atezolizumab
1200 mg every
3 weeks
ORR 23% (95% CI 16-31) in
total population
36
Study 1108 (phase
II)/durvalumab
Urothelial carcinoma
(n = 191)
Second-line Durvalumab
10 mg/kg every
2 weeks
ORR 17.8% (95% CI 12.7-24.0)
in all patients, 27.6% (95% CI
19.0-37.5) for PD-L1≥ 25%, and
5.1% (95% CI 1.4-12.5) for
PD-L1-negative
38
JAVELIN Solid
Tumor (phase I)/
avelumab
Urothelial carcinoma
(n = 249)
Second-line Avelumab
10 mg/kg every
2 weeks
ORR 17.4% (95% CI 11.9-24.1,
complete response in 6.2%) for
61 post-platinum patients ≥6
months of follow-up
40
CheckMate 025
(phase III)/
nivolumab
Advanced RCC
(n = 821)
Second-line Nivolumab
3 mg/kg every
2 weeks
Everolimus 10 mg daily OS 25.0 mos vs. 19.6 mos (HR
0.73, 98.5% CI 0.57-0.93,
p = 0.002)
41
FDA Food and Drug Administration, PD-1 programmed cell death 1, PD-L1 programmed death ligand 1, ORR overall response rate, CI confidence interval, OS
overall survival, HR hazard ratio, PFS progression-free survival, RCC renal cell carcinoma
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patients, ORR was 17.8% (95% CI 12.7-24.0) in all pa-
tients, 27.6% (95% CI 19.0-37.5) for PD-L1 ≥ 25%, and
5.1% (95% CI 1.4-12.5) for PD-L1-negative. Grade 3-4
AEs related to treatment were seen in only 6.8% of
patients.
Avelumab
Avelumab (PD-L1 inhibitor) received accelerated ap-
proval for locally advanced or metastatic UC following
the JAVELIN Solid Tumor study [39]. In this phase Ib
study, 44 patients with metastatic or locally advanced
solid tumors after platinum-based therapy were given es-
calating doses of avelumab 10 mg/kg every 2 weeks. The
primary endpoint was safety and 1 dose-limiting toxicity
was reported at dose level 4 in a patient with metastatic
thymoma who developed autoimmune disorder and in-
creased blood creatine phosphokinase (CPK). Grade 3-4
treatment-related AEs occurred in 3 patients (6.8%) and
included asthenia, AST elevation, elevated CPK, and de-
creased appetite.
In the phase Ib update to the JAVELIN Solid
Tumor study (Table 4), dose-expansion occurred up
to 249 patients with metastatic UC refractory to
platinum-based therapy or ineligible for cisplatin-
therapy [40]. In 161 post-platinum patients with
≥6 months of follow-up, responses were seen across
PD-L1 expression levels tested (≥5% and < 5% PD-L1
tumor cell-staining (25.4% and 13.2%, respectively).
Immune-related AEs occurred in 34 pts. (13.7%) with
an incidence of grade ≥ 3 events in 2.4%.
Renal cell carcinoma
Nivolumab
On November 23, 2015, nivolumab became the first PD-1
inhibitor approved for use in treatment-refractory clear-
cell renal cell carcinoma (RCC) based on results from
CheckMate 025 [41]. In this phase III study, 821 patients
were randomized to receive nivolumab 3 mg/kg every
2 weeks or oral everolimus 10 mg daily (Table 4). The pri-
mary endpoint was OS, which was 25.0 months with nivo-
lumab and 19.6 months with everolimus. Of note, patients
with ≥1% PD-L1 expression demonstrated median OS of
21.8 months with nivolumab and 18.8 months with evero-
limus. Similar results were seen in patients with ≥5% PD-
L1 expression, though interpretation is limited by the
small sample size in this subgroup. The most frequent
grade ≥ 3 AEs were fatigue with nivolumab and anemia
with everolimus (19% and 37%, respectively).
Head and neck cancer
Pembrolizumab
On August 5, 2016, pembrolizumab received accelerated
approval for recurrent or metastatic HNSCC with dis-
ease progression on or after platinum-containing
chemotherapy [42]. The KEYNOTE-012 open-label,
multicenter, phase Ib trial studied the efficacy and safety
of pembrolizumab in patients with ≥1% of tumor cells
that were PD-L1-positive. Sixty patients received pem-
brolizumab 10 mg/kg every 2 weeks for 24 months and
the primary endpoints were safety and ORR per RECIST
1.1 (Table 5). The ORR was 18% (95% CI 8-32%) and 10
(16.7%) experienced grade ≥ 3 AEs with the most com-
mon being transaminitis, hyponatremia, and rash.
Nivolumab
On November 10, 2016, nivolumab became the first im-
munotherapy approved by the FDA for HNSCC based
on results from CheckMate 141 [43]. This phase III trial
randomized 361 patients with disease that recurred or
progressed within 6 months of the last dose of
platinum-containing chemotherapy to nivolumab 3 mg/
kg every 2 weeks or ICC (Table 5). The primary end-
point was OS, which was 7.5 months with nivolumab
and 5.1 months with ICC. Estimated 6-month PFS rates
were 19.7% (nivolumab) and 9.9% (ICC). Grade ≥ 3
nivolumab-related AEs occurred in 13% and included fa-
tigue, anemia, asthenia, and stomatitis. Grade ≥ 3
chemotherapy-related AEs were seen in 35% and most
commonly were anemia and neutropenia.
Hodgkin lymphoma
Pembrolizumab
On March 15, 2017, pembrolizumab received approval
for a hematologic malignancy based on the findings
from the KEYNOTE-087 trial (Table 5) [44]. Patients (n
= 210) with relapsed or refractory classical Hodgkin
Lymphoma (cHL from 3 cohorts: 1.) after autologous
stem cell transplantation (ASCT) and subsequent bren-
tuximab vedotin (BV), 2.) after salvage chemotherapy
and BV with chemoresistant disease, and 3.) after ASCT
but without BV after transplantation received pembroli-
zumab 200 mg every 3 weeks for a maximum of
24 weeks. The ORR was 73.9% for cohort 1, 64.2% for
cohort 2, and 70.0% for cohort 3. The most common
grade ≥ 3 treatment-related AE was neutropenia (2.4%).
Nivolumab
On May 17, 2016, nivolumab received the first approval for
a PD-1 inhibitor in the treatment of a hematologic malig-
nancy based on the findings from CheckMate 039 and
CheckMate 205 (Table 5) [45, 46]. CheckMate 039 was a
phase I study consisting of dose-escalation and expansion
cohorts of patients with relapsed or refractory hematologic
cancers treated with nivolumab 1 mg/kg with escalation to
3 mg/kg, and patients in the expansion cohort received
nivolumab 3 mg/kg at week 1, week 4, and every 2 weeks
up to 2 years [45]. The primary endpoint was safety, and of
the 23 patients with cHL enrolled, grade ≥ 3 AEs were seen
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in 5 patients including myelodysplastic syndrome, pancrea-
titis, and pneumonitis. Results of this trial showed promis-
ing efficacy of nivolumab in cHL.
The CheckMate 205 trial was a phase II study enrolling
80 patients with cHL who had relapsed after ASCT or BV
to receive nivolumab 3 mg/kg every 2 weeks [46]. The pri-
mary endpoint was independently assessed ORR and was
66.3% (53/80 patients) with 52 of the 53 responders hav-
ing > 50% tumor reduction. Notably, in a post-hoc analysis
of patients who did not have response to BV as the most
recent treatment prior to trial recruitment, 31 of 43 pa-
tients achieved objective response after nivolumab treat-
ment. Grade ≥ 3 AEs were seen in 25%, the most frequent
of which were increased lipase and neutropenia.
Microsatellite instability or mismatch repair
deficient cancers
Pembrolizumab
In the first tissue-agnostic indication for a therapeutic
agent, pembrolizumab was approved on May 23, 2017
Table 5 Registration trials leading to the FDA approval of PD-1/PD-L1 inhibitors in head and neck cancer, classical Hodgkin
lymphoma, colorectal cancer, gastroesophageal cancer, hepatocellular cancer, and other solid cancers
Study/Agent Tumor (n) Line of therapy Experimental
arm
Control arm Primary endpoint Ref.
KEYNOTE-012
(phase Ib)/
pembrolizumab
HNSCC (n = 60) PD-L1≥ 1% and
refractory to
platinum chemotherapy
Pembrolizumab
10 mg/kg every
2 weeks
Safety 45% with serious AEs,
17% with grade 3-4 AEs (most
common transaminitis,
hyponatremia, and rash)
ORR 18% (95% CI 8-32%)
42
CheckMate 141
(phase III)/
nivolumab
HNSCC (n = 361) Previously treated with
platinum-based
chemotherapy
Nivolumab
3 mg/kg every
2 weeks
ICC: either weekly
cetuximab
250 mg/m2 after a
loading dose of
400 mg/m2,
weekly
methotrexate 40-
60 mg/m2, or
weekly docetaxel
30-40 mg/m2
OS 7.5 mos vs. 5.1 mos (HR
0.70, 97.73% CI 0.51-0.96,
p = 0.01)
43
KEYNOTE-087
(phase II)/
pembrolizumab
cHL (n = 210) Relapsed after ≥3 lines
of therapy or refractory
cHL
Pembrolizumab
200 mg every
3 weeks
ORR 69.0% (95% CI 62.3-
75.2%)
CR 22.4% (95% CI 16.9- 28.6%)
44
CheckMate 039
(phase I),
CheckMate 205
(phase II)/nivolumab
cHL (n = 80) Previously treated with
ASCT or brentuximab
Nivolumab
3 mg/kg every
2 weeks
ORR 66.3% (95% CI 54.8-76.4) 45,
46
Five phase I and II
trials (including
KEYNOTE-164 and
KEYNOTE-158)/
pembrolizumab
MSI-H or dMMR
unresectable or
metastatic solid
tumors (n = 149
across five trials)
Treatment-refractory to
all standard therapies
Pembrolizumab
200 mg every
3 weeks
ORR 39.6% 47-
53
KEYNOTE-059 (phase II)/
pembrolizumab
Advanced gastric
or gastroesophageal
junction cancer
(n = 259)
PD-L1≥ 1% and
progression on ≥2
lines of chemotherapy
Pembrolizumab
200 mg every
3 weeks
ORR 11.2% (95% CI 7.6-15.7) 54
CheckMate 142
(phase II)/
nivolumab
Metastatic colorectal
cancer (n = 74)
Previously treated with
fluoropyrimidine,
oxaliplatin, and irinotecan
Nivolumab
3 mg/kg every
2 weeks
ORR 31.1% (95% CI 20.8-42.9) 55
CheckMate 040
(phase 1/2)
Advanced
hepatocellular
carcinoma (n = 262)
Refractory to one
previous line of therapy
(including sorafenib), or
intolerant of sorafenib
Nivolumab
3 mg/kg every
2 weeks
Safety 12/48 patients (25%)
grade 3-4 AEs with 3 (6%)
having treatment-related
serious AEs (pemphigoid,
adrenal insufficiency,
liver disorder)
ORR 20% (95% CI 15-26%)
56
JAVELIN Merkel 200
(phase II)
Merkel cell
carcinoma (n = 88)
First-line and beyond Avelumab
10 mg/kg every
2 weeks
ORR 31.8% (95.9%
CI 21.9-43.1)
57
FDA Food and Drug Administration, PD-1 programmed cell death 1, PD-L1 programmed death ligand 1, HNSCC head and neck squamous cell carcinoma, AEs
adverse events, ORR overall response rate, CI confidence interval, ICC investigator-choice chemotherapy, OS overall survival, HR hazard ratio, cHL classical Hodgkin
lymphoma, CR complete response, ASCT autologous stem cell transplantation, MSI-H microsatellite instability-high, dMMR defective mismatch repair
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(Table 5) for patients with treatment-refractory unresect-
able or metastatic solid tumors that are microsatellite
instability-high (MSI-H) or mismatch repair deficient
(dMMR) [47–53]. Two phase 2 studies have showed
ORR of 48% in 29 patients and 50% in 10 patients with
various dMMR cancers, while a pivotal phase 2 study
identified an ORR of 40% in 10 dMMR colorectal cancer
(CRC) patients and an ORR of 71% in 7 dMMR non-
CRC patients [48, 52, 53]. As part of the ongoing, global,
multicenter phase II studies KEYNOTE-164 and
KEYNOTE-158, the ORR was 26.2% for 61 MSI-H CRC
patients and 42.9% for 21 MSI-H non-CRC patients
[47]. In 2 trials evaluating the role pembrolizumab in
dMMR tumors, ORR was 50% in 28 dMMR CRC
patients and 53% in 78 patients with various dMMR
tumors [50, 51]. Another single-institution phase II
study reported an ORR of 56% in 9 patients with dMMR
endometrial cancer [49].
Gastric cancer
Pembrolizumab
Recently on September 22, 2017, pembrolizumab
200 mg every 3 weeks was approved for advanced gas-
troesophageal cancer that is PD-L1 ≥ 1% (IHC 22C3
antibody) and refractory ≥2 lines of chemotherapy based
on the phase II KEYNOTE-059 trial [54]. Out of 259
patients, the ORR was 11.2% (95% CI 7.6-15.7) with a
median duration of response of 8.1 months (Table 5).
Grade 3-5 treatment-related AEs occurred in 43 patients
(16.6%) leading to discontinuation in 2 patients and
death in 2 patients due to renal failure and pleural
effusion.
Colorectal cancer
Nivolumab
On August 1, 2017, nivolumab was approved in dMMR/
MSI-H metastatic colorectal cancer (mCRC) refractory
to fluoropyrimidine, oxaliplatin, and irinotecan [55]. This
approval was granted based on results from the Check-
Mate 142 trial, a phase II trial in which patients received
nivolumab 3 mg/kg every 2 weeks and were stratified by
PD-L1 < 1% and PD-L1 ≥ 1%. The primary endpoint was
ORR per RECIST 1.1. Of the 74 patients enrolled, 23
patients (31%) achieved ORR irrespective of PD-L1
levels (Table 5). Nivolumab-related grade ≥ 3 AEs
occurred in 12% of patients, most commonly fatigue,
diarrhea, and pruritus.
Hepatocellular carcinoma
Nivolumab
Recently on September 22, 2017, nivolumab 3 mg/kg
every 2 weeks was approved in advanced hepatocellular
carcinoma (HCC) refractory to sorafenib in the phase I/
II CheckMate 040 trial [56]. Of 262 eligible patients,
ORR was 20% (95% CI 15-26%) with no maximum-
tolerated dose established in the dose-escalation phase.
Activity and tolerability did not appear to be affected by
PD-L1 status or presence or absence of viral hepatitis
(Table 5). Twelve of 48 patients (25%) experienced grade
3-4 AEs with 3 patients (6%) having treatment-related
serious AEs (pemphigoid, adrenal insufficiency, liver
disorder).
Merkel cell carcinoma
Avelumab
Avelumab, a fully humanized monoclonal IgG1 antibody
against PD-L1, was first approved on March 23, 2017 for
treatment of metastatic Merkel cell carcinoma
(untreated and chemotherapy-resistant). This approval
was granted based on the results of the JAVELIN trial, a
single-arm phase II trial in which patients with stage 4
Merkel cell carcinoma refractory to ≥1 previous line of
chemotherapy received IV avelumab 10 mg/kg every
2 weeks [57]. The primary endpoint was ORR (Table 5).
Complete response was observed in 9% of patients and
partial response observed in 23%, at a median follow-up
time of 10.4 months. Among the patients whose tumors
were assessable for PD-L1 expression (with PD-L1 posi-
tivity defined as a threshold level of 1% positive cells of
any intensity), 34.5% (95% CI, 22.5-48.1) achieved object-
ive responses. Grade ≥ 3 toxicities were reported in 5%
of patients including lymphopenia and isolated labora-
tory abnormalities.
Discussion
Since the FDA approvals of the first PD-1 inhibitors
pembrolizumab and nivolumab in 2014, the clinical
development of PD-1 and PD-L1 inhibitors as anticancer
agents has picked up considerable momentum [13–15,
18]. There are currently 5 PD-1/PD-L1 inhibitors that
are FDA-approved in the treatment of a number of solid
tumors (Tables 1, 2, 3, 4 and 5). Approved indications in
this class of immune checkpoint inhibitors have also
expanded to include hematologic malignancies and spe-
cific molecular phenotypes irrespective of solid tumor
histology (i.e., tissue-agnostic) [45–53, 55]. As the
number of PD-1/PD-L1 inhibitors undergoing develop-
ment is expected to rise in the foreseeable future, several
important points of discussion need to be considered in
order to optimize the anticancer potential of this class of
agents.
Predictive biomarkers
Despite the promising anticancer activity offered by PD-
1 and PD-L1 inhibitors, predicting tumor responses to
PD-1/PD-L1 blockade remains a challenge given that
not all patients derive benefit from this class of immuno-
therapy. Perhaps the earliest and most widely recognized
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predictive biomarker of response to PD-1/PD-L1 block-
ade is PD-L1 expression, for which there are 4 FDA-
approved assays of PD-L1 expression by IHC (Table 1)
to help guide treatment decisions for nivolumab in
advanced NSCLC or melanoma (Dako 28-8), pembroli-
zumab in advanced NSCLC (Dako 22C3), atezolizumab
in advanced urothelial carcinoma or NSCLC (Ventana
SP142), and durvalumab in advanced urothelial carcin-
oma (Ventana SP263) [20, 24, 27, 28, 35, 37, 38]. A
recent meta-analysis involving 41 clinical trials and 6664
patients with advanced solid tumors investigated the
predictive value of tumor and tumor-infiltrating immune
cell PD-L1 expression by IHC assays such as Dako 28-8,
Dako 22C3, Ventana SP142, Ventana SP263, and Dako
clone 73-10 and demonstrated that PD-L1 expression
was predictive of tumor response across all tumor types
(odds ratio (OR) 2.26, 95% confidence interval (CI) 1.85-
2.75, p < 0.001) [58]. Of note, the largest effect reaching
significance was observed in NSCLC (OR 2.51, 95% CI
1.99-3.17, p < 0.001). However, despite the promising
utility of PD-L1 expression as a biomarker for PD-1/PD-
L1 blockade, there is growing concern regarding its true
predictability for response given its highly variable, het-
erogeneous, and dynamic expression on tumor or
tumor-infiltrating immune cells [12]. Furthermore, tech-
nical differences and variation in screening thresholds
for PD-L1 expression across assays represent additional
limitations. This was shown in a recent multi-
institutional collaborative effort to provide information
on the analytic comparability of the 4 FDA-approved
IHC assays of PD-L1 expression (22C3, 28-8, SP142, and
SP263) [59]. Out of 39 NSCLC tumors stained, 3/4
assays showed a comparable percentage of PD-L1-
stained tumor cells while the SP142 assay showed fewer
stained tumor cells overall. There was greater variability
in immune cell staining than tumor cell staining across
all 4 assays. Notably, in 14/38 cases (37%) a different
PD-L1 classification would have been made depending
on which IHC assay and scoring system was used. A lar-
ger Phase II effort is currently underway to validate
these findings. Nevertheless, although PD-L1 expression
is associated with a higher likelihood of response to PD-
1/PD-L1 blockade, it has yet to be proven as the defini-
tive biomarker for efficacy and its absence certainly does
not preclude response to PD-1/PD-L1 inhibitors.
The search for the ideal biomarker of response to PD-
1/PD-L1 blockade is undergoing active investigation.
There is increasing evidence to support that high muta-
tional load can predict benefit from immune checkpoint
inhibitors across several tumor types due to the
immunogenic nature of neoantigens generated from an
increased burden of nonsynonymous mutations [60]. For
example, MSI or dMMR tumors are predisposed to
accumulation of frameshift mutations due to defective
DNA repair machinery and have shown significantly
greater responses to PD-1 blockade compared to micro-
satellite stable (MSS) or mismatch repair-proficient tu-
mors [47–53, 55]. Tumors harboring POLE mutations
represent another phenotype with high tumor muta-
tional burden that may predict response to PD-1 block-
ade [60, 61]. Other investigations have focused on the
presence of an immune-active TME. Here, a TME asso-
ciated with higher densities of CD8+ tumor-infiltrating
lymphocytes (TILs) with a Th1 phenotype and more
clonal T-cell receptor (TCR) repertoire, higher levels of
interferon (IFN), IFN-γ-inducible genes, and IFN-
stimulated chemokines such as CXCL9, CLCL10, and
CXCL11, and high levels of immune checkpoints such
as cytotoxic T-lymphocyte antigen 4 (CTLA-4), PD-L1/
PD-L2, PD-1, and indoleamine 2,3-dioxygenase (IDO)
may predict benefit from anti-PD-1 and anti-PD-L1
therapy [12, 60, 62]. In contrast to the immunologically
“hot” TME, “cold” or non-T-cell-inflamed tumors have
been associated with activated Wnt/β-catenin pathway
signaling and PTEN deficiency [60, 62]. Features that de-
fine an immunologically hot or T-cell-inflamed tumor
are becoming increasingly complex with evidence to
support a role for CD4+ T-cells, T-regulatory cells, and
myeloid-derived suppressor cells in contributing to a
TME that is responsive to PD-1/PD-L1 blockade [60,
62].
Lastly, genetic polymorphisms and composition of the
gut microbiome may also shape an individual’s potential
to respond to immune checkpoint inhibitors, and pro-
spective studies are underway to investigate these novel
concepts [12, 60, 62]. Significant differences in baseline
diversity and composition of the gut microbiome
between responders and nonresponders to anti-PD-1
therapy in metastatic melanoma patients have been
reported, with enrichment of the Ruminococcaceae fam-
ily of the Clostridiales order in responders whereas the
Prevotellaceae family of the Bacteroidales order was
enriched in nonresponders [63]. Other studies in melan-
oma mice models have identified that commensal gut
bacteria such as Bifidobacterium putatively enhance
response to anti-PD-L1 therapy by modulating immune
responses through T-cell regulatory pathways [64]. Con-
versely, antibiotics can affect 30% of gut microbiota, and
retrospective analyses in advanced solid tumor patients
treated with anti-PD-1/PD-L1 therapy showed that
receipt of antibiotics prior to immunotherapy was a
negative predictor of survival on multivariate analysis
[65]. Future directions of investigation may seek to
explore the utility of a comprehensive assessment that
takes into account features of the TME and other
immune parameters to produce a composite score pre-
dictive of benefit to PD-1/PD-L1 blockade; one such
tool, the Immunoscore, has already been demonstrated
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as a strong prognostic indicator in CRC with potential
to guide immunotherapy strategies [66].
Mechanisms of resistance and hyperprogressors
Blockade of the PD-1/PD-L1 axis results in antitumor activ-
ity due to its ability, in part, to inhibit interferon-induced
adaptive immune resistance characterized by interferon-
induced JAK-STAT signaling that results in activation of
interferon regulatory factor 1 (IRF1) and expression of PD-
L1 and IDO that allow for cancer cell immune evasion [67].
Innate resistance to anti-PD-1 therapy has been character-
ized by upregulation of genes involved in the regulation of
cell adhesion, extracellular matrix remodeling, mesenchy-
mal transition, angiogenesis, and wound healing [68].
Acquired resistance to checkpoint blockade has been char-
acterized by loss of sensitivity to IFN-γ either through mu-
tations or epigenetic silencing of mediators of the IFN-γ//
JAK/STAT/IRF1 signaling pathway [67, 69]. In addition,
one study was among the first to describe the existence of a
subset of patients (9%) experiencing hyperprogressive dis-
ease defined as RECIST progression at first evaluation char-
acterized by a ≥ 2-fold increase in tumor growth rate in
response to anti-PD-1/PD-L1 therapy [70]. This novel pat-
tern of hyperprogression was associated with higher age
and worse OS. In a separate study, tumors from 155
patients with advanced cancers treated with PD-1/PD-L1
inhibitors were evaluated by next-generation sequencing to
evaluate potential genomic markers associated with hyper-
progressive disease defined as time-to-treatment failure
(TTF < 2 months, > 50% increase in tumor burden
compared to pre-immunotherapy imaging, and > 2-
fold increase in progression pace [71]. Hyperproges-
sors to single-agent PD-1/PD-L1 blockade were found
to have MDM2 family amplifications or EGFR aberra-
tions that significantly correlated to a TTF < 2 months
on multivariate analysis.
Further understanding of mechanisms of resistance
and identification of hyperprogressors are certainly war-
ranted in large, prospective cohorts to optimize efficacy
and minimize risk to PD-1/PD-L1 inhibitors. Moreover,
given the complexities of immunoregulatory pathways
and host and tumor heterogeneity, combination strat-
egies incorporating PD-1/PD-L1 blockade with vaccines,
radiation therapy, stimulators of T-cell activity through
targeting of CD40/CD40L, OX40/OX40L, and 4-1BB
(CD137), co-targeting of other immune checkpoints
such as T-cell immunoglobulin mucin 3 (Tim-3),
lymphocyte activation gene 3 protein (LAG3), IDO, and
T-cell immunoglobulin and ITIM domain (TIGIT),
adoptive T-cell therapy, epigenetic reprogramming
drugs, chemotherapy, and targeted agents such as vascu-
lar endothelial growth factor (VEGF)-directed therapy
are increasingly being employed in clinical trials to
enhance sensitivity to immunotherapy [62].
Immune-related adverse events
Paramount to the safe and effective administration of
anti-PD-1 and anti-PD-L1 therapy is our greater recog-
nition and understanding of their potential immune-
related toxicities. A recent meta-analysis of 3450 patients
receiving PD-1/PD-L1 inhibitors demonstrated higher
risk of all-grade rash, pruritus, hypothyroidism, hyper-
thyroidism, colitis, aminotransferase elevations, and
pneumonitis but lower risk of all-grade AEs in general
and lower risk of all-grade fatigue, sensory neuropathy,
diarrhea, hematologic toxicities, anorexia, nausea, and
constipation, and treatment discontinuation when com-
pared to chemotherapy [72]. Nevertheless, immune-
related toxicities can often be nontrivial resulting in sig-
nificant risks that outweigh potential benefits of PD-1/
PD-L1 inhibitors. For example, beginning July 2017, the
FDA has placed clinical holds on several clinical trials
investigating pembrolizumab-, nivolumab-, and
durvalumab-containing regimens in various hematologic
malignancies based on findings and safety concerns
identified from the KEYNOTE-183 and KEYNOTE-185
studies [73–75]. A detailed description of specific
immune-related AEs and their management is beyond
the scope of this review and has been extensively
reviewed elsewhere; however, there is growing evidence
that reassuringly shows use of systemic immunosuppres-
sants may not negatively impact outcomes derived from
checkpoint blockade [76–80].
Treatment duration, treatment beyond progression, and
response after prior PD-1/PD-L1 blockade
The optimal duration of treatment with PD-1/PD-L1
inhibitors remains undefined but is of increasing rele-
vance given the potential for delayed responses and the
uncommon but documented phenomenon of pseudo-
progression with immune checkpoint inhibitors [81].
Many randomized clinical trials investigating anti-PD-1
therapy across several tumor types have allowed for
treatment beyond first progression (TBP) provided that
patients continued to exhibit investigator-assessed clin-
ical benefit, stable performance status, and tolerance to
therapy without substantial adverse effects [81].
Available post hoc subgroup analyses of these trials have
demonstrated that 9-48% of patients received TBP ≥4 or
6 weeks with anti-PD-1 therapy, and of these, 13-33% of
patients experienced > 30% target lesion reduction after
progression when compared to baseline imaging [81–
85]. Compared to non-TBP patients, TBP patients often
showed improved PFS and OS though often with higher
incidence of treatment-related AEs consistent with pro-
longed exposure to anti-PD-1 therapy. It remains
unclear, however, whether patients who experienced
additional benefit with TBP had contributing factors
such as better prognostic features and likely more
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indolent disease to begin with and whether the small
subset of the overall population of patients that benefit
from TBP is worth the increased toxicity, increased cost,
and risk of delaying alternative and more effective ther-
apies in choosing this approach [81]. Furthermore, many
randomized clinical trials have employed conventional
RECIST criteria to assess the efficacy of PD-1 inhibitors
[82–86]. The novel iRECIST criteria has recently been
proposed to allow more consistent interpretation of re-
sponse and progression to cancer immunotherapy [87].
For the question of response to PD-1/PD-L1 blockade
after prior treatment with PD-1/PD-L1 inhibitors, evi-
dence is limited but appears to support an unlikely re-
sponse with subsequent treatment in this scenario; there
are, however, numerous ongoing and pending prospect-
ive clinical trials involving PD-1/PD-L1 blockade that
allow prior treatment with PD-1/PD-L1 inhibitors that
may provide more information on this topic [88]. Future
studies of ideally prospective design are warranted to ad-
dress remaining questions on optimal duration, TBP vs.
switching to agents of a different class on progression,
and treatment to progression or best response followed
by rechallenge with PD-1/PD-L1 inhibitors.
Clinical trial design
Lastly, several confirmatory phase III trials KEYNOTE-
040, IMVigor211, and CheckMate 026 have failed to meet
their primary endpoints of PFS or OS despite promising
results in prior studies that in some instances resulted in
earlier FDA approval [89–91]. Differences in patient selec-
tion and baseline characteristics, variation among bio-
marker assays and PD-L1 expression cut-off thresholds,
sampling for PD-L1 expression on metastatic lesions vs.
archival tissue biopsy, subsequent immunotherapy in the
standard of care arms, and outperformance or over-
achievement of study assumptions by standard of care
therapies have been among the many, but not all, potential
explanations for these recent results [89, 90, 92, 93]. There
is curiosity regarding the fate of FDA-labeled indications
for specific PD-1/PD-L1 inhibitors that were earlier
approved but dependent on confirmatory phase III trials.
Nevertheless, these negative trials highlight the import-
ance of all aspects of clinical trial design in evaluating the
efficacy of immune checkpoint inhibitors and provide
invaluable learning for subsequent confirmatory trials.
Furthermore, others have proposed implementation of
iRECIST criteria and incorporation of weighted-log rank
tests into future study designs as considerations to
improve our interpretability of success or failure with PD-
1/PD-L1 inhibitors [87, 94].
Conclusions
Since the FDA approvals of the first PD-1 inhibitors
pembrolizumab and nivolumab in 2014, the clinical
development of PD-1/PD-L1 inhibitors as a form of can-
cer immunotherapy has seen unprecedented growth.
There are currently 5 PD-1/PD-L1 inhibitors that are
approved for the treatment of a spectrum of cancers
including hematologic malignancies. As the number of
anti-PD-1 and anti-PD-L1 therapies is expected to rise
in the foreseeable future, there are several key issues that
remain and require further investigation in order to
optimize the anticancer potential of this class of agents.
Specifically, predictive biomarkers, mechanisms of
resistance, immune-related toxicities, hyperprogressors,
treatment duration and TBP, and clinical trial design
represent areas in need of further consideration to
optimize benefit and minimize risks from PD-1/PD-L1
blockade.
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